SEC Form 4 · accession 0001237899-15-000011
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Powchik
Officer — SVP Clinical Development & Reg
Period of report
Dec 31, 2014
Accepted (ET)
Jan 5, 2015 · 4:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 31, 2014 | M | 25,000 | $52.03 | A | 35,711 | D | |
| Common Stock | Dec 31, 2014 | F | 3,151 | $412.78 | D | 32,560 | D | |
| Common Stock | Dec 31, 2014 | F | 11,027 | $412.78 | D | 21,533 | D | |
| Common StockF2 | Jan 2, 2015 | S | 1,400 | $410.99 | D | 20,133 | D | |
| Common StockF3 | Jan 2, 2015 | S | 1,122 | $411.99 | D | 19,011 | D | |
| Common StockF4 | Jan 2, 2015 | S | 1,700 | $412.81 | D | 17,311 | D | |
| Common StockF5 | Jan 2, 2015 | S | 2,758 | $414.07 | D | 14,553 | D | |
| Common StockF6 | Jan 2, 2015 | S | 1,642 | $415.20 | D | 12,911 | D | |
| Common StockF7 | Jan 2, 2015 | S | 900 | $416.75 | D | 12,011 | D | |
| Common StockF8 | Jan 2, 2015 | S | 1,000 | $417.44 | D | 11,011 | D | |
| Common StockF9 | Jan 2, 2015 | S | 300 | $418.40 | D | 10,711 | D | |
| Common Stock | holding | — | — | — | 18,000 | I | by GRAT | |
| Common Stock | holding | — | — | — | 1,621 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F10 | $52.03 | Dec 31, 2014 | M | 25,000 | D | — | Dec 16, 2021 | Common Stock | 25,000 | 37,079 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F10The option became exercisable with respect to all shares underlying the option on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014.
- F2Represents volume-weighted average price of sales of 1,400 shares of Company stock on January 2, 2015 at prices ranging from $410.48 to $411.36. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2015 at each separate price.
- F3Represents volume-weighted average price of sales of 1,122 shares of Company stock on January 2, 2015 at prices ranging from $411.53 to $412.44. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2015 at each separate price.
- F4Represents volume-weighted average price of sales of 1,700 shares of Company stock on January 2, 2015 at prices ranging from $412.58 to $413.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2015 at each separate price.
- F5Represents volume-weighted average price of sales of 2,758 shares of Company stock on January 2, 2015 at prices ranging from $413.75 to $414.56. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2015 at each separate price.
- F6Represents volume-weighted average price of sales of 1,642 shares of Company stock on January 2, 2015 at prices ranging from $414.97 to $415.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2015 at each separate price.
- F7Represents volume-weighted average price of sales of 900 shares of Company stock on January 2, 2015 at prices ranging from $416.00 to $416.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2015 at each separate price.
- F8Represents volume-weighted average price of sales of 1,000 shares of Company stock on January 2, 2015 at prices ranging from $417.03 to $417.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2015 at each separate price.
- F9Represents volume-weighted average price of sales of 300 shares of Company stock on January 2, 2015 at prices ranging from $418.16 to $418.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2015 at each separate price.